Stem Cells to Treat Lung Disease in Preterm Infants
Cincinnati, OH, February 6, 2014
Advances in neonatal care for very preterm infants have
greatly increased the chances of survival for these fragile infants. However, preterm infants have an increased
risk of developing bronchopulmonary dysplasia (BPD), a serious lung disease,
which is a major cause of death and lifelong complications. In a new study scheduled for publication in
The Journal of Pediatrics, researchers evaluated the safety and feasibility of
using stem cell therapies on very preterm infants to prevent or treat BPD.
Won Soon Park, MD, PhD, and colleagues from Samsung Medical Center and Biomedical Research Institute, Seoul, Republic of Korea, conducted a phase I, single-center trial of intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells to nine very preterm infants (24-26 weeks gestational age) who were at high risk of developing BPD.
All patients who received the treatment tolerated the procedure well without any immediate serious adverse effects. Thirty-three percent of treated infants developed moderate BPD and none developed severe BPD, and 72 percent of a matched comparison group developed moderate or severe BPD. Another serious side effect of very preterm birth, retinopathy of prematurity requiring surgery, tended to occur less often in treated infants. Overall, all nine treated infants survived to discharge, and only three developed moderate BPD.
This phase I study suggests that intratracheal administration of mesenchymal stem cells is safe and feasible. According to Dr. Park, "These findings strongly suggest that phase II clinical trials are warranted to test the efficacy of mesencymal stem cell transplantation, which could lead to new therapies to prevent or cure BPD." Dr. Park and colleagues are currently conducting a long-term safety and follow-up study of these nine preterm infants (ClinicalTrials.gov: NCT01632475).
# # #
Notes for editors
"Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial," by Yun Sil Chang, MD, PhD, So Yoon Ahn, MD, Hye Soo Yoo, MD, Se In Sung, MD, Soo Jin Choi, MD, PhD, Won Il Oh, MD, PhD, Woon Soon Park, MD, appears in The Journal of Pediatrics (www.jpeds.com), DOI 10.1016/j.jpeds.2013.12.011, published by Elsevier.
About The Journal of Pediatrics
The Journal of Pediatrics is a primary reference for the science and practice of pediatrics and its subspecialties. This authoritative resource of original, peer-reviewed articles oriented toward clinical practice helps physicians stay abreast of the latest and ever-changing developments in pediatric medicine. The Journal of Pediatrics is ranked 4th out of 121 pediatric medical journals (2012 Journal Citation Reports®, published by Thomson Reuters). URL: www.jpeds.com
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 513 636 7140